Phase 1/2 Study to Determine the Safety, Pharmacokinetics and Efficacy of the TGFB2 Targeting Anti-sense ODN OT-101 in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Latest Information Update: 06 Dec 2022
At a glance
- Drugs Trabedersen (Primary)
- Indications Diffuse intrinsic pontine glioma
- Focus Therapeutic Use
- 06 Dec 2022 New trial record
- 30 Nov 2022 According to an Oncotelic media release, trial design from this study presented at the Society for Neuro-Oncology (SNO) 27th Annual Meeting.